BioAtla to Participate in the Citizens Life Sciences Conference
BioAtla (Nasdaq: BCAB), a global clinical-stage biotechnology company, has announced its upcoming participation in the Citizens Life Sciences Conference in New York. The company, which specializes in developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumor treatment, will deliver a corporate update and engage in one-on-one investor meetings.
The presentation is scheduled for Wednesday, May 7, 2025, at 10:00 a.m. ET in New York. Company management will be available for individual investor discussions during the two-day conference, which runs from May 7-8, 2025. A webcast link has been provided for those interested in following the corporate update remotely.
BioAtla (Nasdaq: BCAB), un'azienda biotecnologica globale in fase clinica, ha annunciato la sua partecipazione imminente alla Citizens Life Sciences Conference a New York. L'azienda, specializzata nello sviluppo di anticorpi terapeutici biologici condizionatamente attivi (CAB) per il trattamento dei tumori solidi, presenterà un aggiornamento aziendale e parteciperà a incontri individuali con gli investitori.
La presentazione è programmata per mercoledì 7 maggio 2025, alle 10:00 ET a New York. Il management dell'azienda sarà disponibile per discussioni individuali con gli investitori durante la conferenza di due giorni, che si svolgerà dal 7 all'8 maggio 2025. È stato fornito un link webcast per chi desidera seguire l'aggiornamento aziendale da remoto.
BioAtla (Nasdaq: BCAB), una empresa biotecnológica global en etapa clínica, ha anunciado su próxima participación en la Citizens Life Sciences Conference en Nueva York. La compañía, especializada en el desarrollo de anticuerpos terapéuticos biológicos condicionalmente activos (CAB) para el tratamiento de tumores sólidos, ofrecerá una actualización corporativa y realizará reuniones individuales con inversores.
La presentación está programada para el miércoles 7 de mayo de 2025, a las 10:00 a.m. ET en Nueva York. La dirección de la empresa estará disponible para discusiones individuales con inversores durante la conferencia de dos días, que se llevará a cabo del 7 al 8 de mayo de 2025. Se ha proporcionado un enlace de webcast para quienes deseen seguir la actualización corporativa de forma remota.
BioAtla (나스닥: BCAB)는 글로벌 임상 단계 생명공학 기업으로, 뉴욕에서 열리는 Citizens Life Sciences Conference에 참가할 예정임을 발표했습니다. 고형암 치료를 위한 조건부 활성 생물학적 항체 치료제(CAB) 개발을 전문으로 하는 이 회사는 기업 업데이트를 제공하고 투자자들과 일대일 미팅을 진행할 예정입니다.
발표는 2025년 5월 7일 수요일 오전 10시(동부시간) 뉴욕에서 예정되어 있습니다. 회사 경영진은 2025년 5월 7일부터 8일까지 이틀간 진행되는 컨퍼런스 기간 동안 개별 투자자 상담에 응할 예정입니다. 원격으로 기업 업데이트를 시청할 수 있도록 웹캐스트 링크도 제공됩니다.
BioAtla (Nasdaq : BCAB), une entreprise biotechnologique mondiale en phase clinique, a annoncé sa prochaine participation à la Citizens Life Sciences Conference à New York. Spécialisée dans le développement de thérapeutiques par anticorps biologiques conditionnellement actifs (CAB) pour le traitement des tumeurs solides, la société présentera une mise à jour corporative et participera à des réunions individuelles avec des investisseurs.
La présentation est prévue pour le mercredi 7 mai 2025 à 10h00 ET à New York. La direction sera disponible pour des discussions individuelles avec les investisseurs lors de cette conférence de deux jours, qui se tiendra du 7 au 8 mai 2025. Un lien de webdiffusion a été mis à disposition pour ceux souhaitant suivre la mise à jour à distance.
BioAtla (Nasdaq: BCAB), ein globales biotechnologisches Unternehmen in der klinischen Entwicklungsphase, hat seine bevorstehende Teilnahme an der Citizens Life Sciences Conference in New York angekündigt. Das Unternehmen, das sich auf die Entwicklung von konditional aktiven biologischen Antikörpertherapeutika (CAB) zur Behandlung solider Tumore spezialisiert hat, wird ein Unternehmensupdate präsentieren und Einzelgespräche mit Investoren führen.
Die Präsentation ist für Mittwoch, den 7. Mai 2025, um 10:00 Uhr ET in New York geplant. Das Management steht während der zweitägigen Konferenz vom 7. bis 8. Mai 2025 für individuelle Gespräche mit Investoren zur Verfügung. Für Interessierte wird ein Webcast-Link bereitgestellt, um das Unternehmensupdate aus der Ferne verfolgen zu können.
- Corporate update presentation at a major investor conference indicating active investor relations and market visibility
- One-on-one investor meetings suggest potential for developing strategic relationships and funding opportunities
- None.
SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will provide a corporate update and participate in one-on-one investor meetings at the Citizens Life Sciences Conference, to be held in New York, NY May 7-8, 2025.
Format: Corporate update and one-on-one investor meetings
Date: Wednesday, May 7, 2025
Time: 10:00 a.m. ET
Location: New York, NY
Webcast Link: Click Here
About BioAtla®, Inc.
BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through its contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary CAB platform technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB platform technology and products with greater than 780 active patent matters, more than 500 of which are issued patents. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. BioAtla’s first dual CAB bispecific T-cell engager antibody, BA3182, is currently in Phase 1 development. BA3182 targets EpCAM, which is highly and frequently expressed on many adenocarcinomas while engaging human CD3 expressing T cells. The Company also has two first-in-class CAB programs currently in Phase 2 clinical testing, mecbotamab vedotin, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab vedotin, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). The Phase 2 stage CAB-CTLA-4 antibody, evalstotug, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and potentially enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibody. To learn more about BioAtla, Inc. visit www.bioatla.com.
Internal Contact:
Richard Waldron
Chief Financial Officer
BioAtla, Inc.
rwaldron@bioatla.com
858.356.8945
External Contact:
Bruce Mackle
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
FAQ
When is BioAtla (BCAB) presenting at the Citizens Life Sciences Conference 2025?
What type of meetings will BioAtla (BCAB) hold at the Citizens Life Sciences Conference?
What is BioAtla's (BCAB) main focus in cancer treatment development?
Where can investors watch BioAtla's (BCAB) Citizens Life Sciences Conference presentation?
How long will BioAtla (BCAB) participate in the Citizens Life Sciences Conference 2025?
